Skip to content

Replimune Group REPL Common Stock, Shares, Outstanding

Common Stock, Shares, Outstanding at other companies

Amgen logo
AmgenAMGN
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
Arcus Biosciences logo
Arcus BiosciencesRCUS
Tango Therapeutics logo
Tango TherapeuticsTNGX
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Immunovant, Inc. logo
Immunovant, Inc.IMVT

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesOutstanding.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's common stock, shares, outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's common stock, shares, outstanding?
Replimune Group (REPL) reported common stock, shares, outstanding of $79.63M in Q4 2025.
How has Replimune Group's common stock, shares, outstanding changed year-over-year?
Replimune Group's common stock, shares, outstanding increased by 3.4% year-over-year, from $77.01M to $79.63M.
What is the long-term trend for Replimune Group's common stock, shares, outstanding?
Over 4 years (2021 to 2025), Replimune Group's common stock, shares, outstanding has grown at a 13.4% compound annual growth rate (CAGR), from $46.57M to $77.09M.